Tango Therapeutics (TNGX) Study result summary

Vopimetostat plus daraxonrasib in PDAC

• In previously treated MTAP-deleted, RAS-mutant PDAC, ORR was 82% (18/22), with all responses confirmed, and DCR was 100%.

• Median PFS was not reached; 9-month PFS was 88% (95% CI: 60–97). Median follow-up was 7.1 months; 13/22 patients received treatment in third line.

• In NSCLC, vopimetostat plus daraxonrasib achieved 80% ORR (4/5) and 100% DCR.

Safety and pharmacology

• The safety population included 34 patients; no Grade 4 or 5 events were reported. At dose level 1, 25 patients had no DLTs, treatment-related withdrawals, or Grade 4/5 TRAEs.

• At dose level 1, Grade 3 TRAEs occurred in 40% of patients and dose reductions in 20%; common TRAEs were stomatitis (48%), rash (44%) and diarrhea (28%), all Grade 1–2.

• Dose level 2 was not well-tolerated, with 3 DLTs in 2 of 4 safety-evaluable patients. At dose level 1, daraxonrasib exposure was similar to 300 mg single-agent daraxonrasib.

Other combination results

• With zoldonrasib in MTAP-deleted, KRAS G12D PDAC, ORR was 54% (19/35), 9-month PFS was 61%, and DCR was 97%; Grade 3 TRAEs occurred in 28%, with one Grade 4 TRAE and no Grade 5 TRAEs.